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Abstract
Retinal neovascularization (NV) is a major cause of blindness in ischemic retinopathies. Previous investigations have
indicated that ischemia upregulates GFAP and PDGF-B expression. GFAP overexpression is a hallmark of reactive gliosis (RG),
which is the major pathophysiological feature of retinal damage. In addition, PDGF-B has been implicated in proliferative
retinopathies. It was the aim of this study to gain insights on the possible pharmacological interventions to modulate PDGF-
B and GFAP expression, and its influence on RG and NV. We used an array of assays to evaluate the effects of YC-1, a small
molecule inhibitor of HIF-1 and a novel NO-independent activator of soluble guanylyl cyclase (sGC), on RG and NV, in vivo
and in vitro. When compared to the DMSO-treated retinas, dual-intravitreal injections of YC-1, in vivo: (1) suppressed the
development and elongation of neovascular sprouts in the retinas of the oxygen-induced retinopathy (OIR) mouse model;
and (2) reduced ischemia-induced overexpression of GFAP and PDGF-B at the message (by 64.1460.5% and 70.2760.04%)
and the protein levels (by 65.5260.02% and 57.5960.01%), respectively. In addition, at 100 mM, YC-1 treatment
downregulated the hypoxia-induced overexpression of GFAP and PDGF-B at the message level in rMC-1 cells (by
71.4260.02% and 7560.03%), and R28 cells (by 58.6260.02% and 50.0060.02%), respectively; whereas, the protein levels of
GFAP and PDGF-B were reduced (by 78.5760.02% and 77.5560.01%) in rMC-1cells, and (by 81.4460.02% and 79.1660.01%)
in R28 cells, respectively. We demonstrate that YC-1 reversed RG during ischemic retinopathy via impairing the expression
of GFAP and PDGF-B in glial cells. This is the first investigation that delves into the reversal of RG during ischemic retinal
vasculopathies. In addition, the study reveals that YC-1 may exert promising therapeutic effects in the treatment of retinal
and neuronal pathologies.
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Introduction
Diabetic retinopathy [DR] is a leading cause of visual
disturbance in adults and is the leading cause of blindness in
Americans between the ages of 20 and 74 years [1]. DR has been
regarded as a retinal microvascular disease, which develops in two
stages: an early, non-proliferative stage, and a later, proliferative
stage. In the early non-proliferative stage, retinal vascular
permeability can increase even before the appearance of clinical
retinopathy [2]. Currently, this stage is diagnosed by dilation of
retinal veins, retinal microaneurysmas, intraretinal microvascular
abnormalities, areas of capillary nonperfusion, retinal hemorrhag-
es, cotton wool spots, edema, and exudates. All of these signs
indicate regional failure of the retinal microvascular circulation,
which presumably results in ischemia. In contrast, proliferative
DR’s [PDR] diagnosis is based on the ischemia-induced formation
of new blood vessels [BVs] on the surface of the retina. New vessels
can extend into the vitreous cavity of the eye and can hemorrhage
into the vitreous, resulting in visual loss [3]. They also can cause
tractional retinal detachments from the accompanying contractile
fibrous tissue. Furthermore, during this stage, over-proliferation of
capillary endothelial cells [ECs] results in retinal neovasculariza-
tion [NV], abnormal formation of new vessels in the retina and the
vitreous, leading to PDR [4]. As a consequence retinal edema may
ensue [5]. Retinal edema involves the breakdown of the blood-
retinal barrier, with leakage of plasma from small BVs.
Platelet-derived growth factors (PDGFs) are growth-regulatory
molecules that stimulate chemotaxis, proliferation, and increased
metabolism of primarily connective tissue cells [6]. In addition,
PDGF is a potent mitogen for mesenchymal cells and glial cells,
which may act as a neuronal regulatory agent. Neuronal release of
PDGF could contribute to nerve regeneration and to glial
proliferation that leads to gliosis and scarring [6]. Furthermore,
glial cells could utilize the elevated levels of PDGF to proliferate in
RG, and under these conditions PDGF may also augment the
immune responses [7]. It is also possible that PDGF increases the
survival, and promotes the neurite outgrowth from grafted
dopaminergic neurons [7]. PDGF-B is a vasoactive factor that
possesses both chemotactic and mitogenic properties to vascular
ECs in vitro [67] and may also have angiogenic effects in vivo [8].
Previous data have indicated that the distributions of PDGF B-
chain-related immunoreactivity [PBRI] in the cerebral wound
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same study has demonstrated that cerebral wound induced the
expression of PDGF B-chain in neurons and macrophages in the
lesion area. This increased expression of PDGF B-chain at a stab
wound was proven to be related strongly to RG [9]. Moreover,
increased expression of PDGF-B in the retina causes plays an
important role in the pathogenesis of PDR and retinal detachment
[10]. PDGF-B promotes the recruitment, proliferation and
survival of pericytes; recruits glial cells [8] and retinal pigment
epithelial [RPE] cells [11] that instigates scarring, which is
ultimately the major cause of permanent loss of vision. Previous
data have revealed that PDGF-B may play a crucial role in RG
following injury [12], as well as it may lead to astrocyte and glial
cell chemotaxis and proliferation [13].
The retina contains two types of macroglial cells. The most
abundant are the Mu ¨ller cells, which project from the retinal
ganglion cell layer [GCL] to the photoreceptors. While the
astrocytes, which originate in the optic nerve and migrate into the
retina during development [14], reside as a single layer adjacent to
the inner limiting membrane [ILM]. Glial cells provide structural
and metabolic support for retinal neurons and BVs. These cells
become reactive in certain injury states [15]. Several studies
suggested that glial reactivity and altered glial metabolism are
early pathological events in the retina during diabetes [16]. The
most constant manifestation of reactivity is the increase in
immunoreactivity for the intermediate filament protein [glial
fibrillary acidic protein] [GFAP] [17]. GFAP is mainly expressed
in astrocytes for which it constitutes a selective marker. Previous
reports have demonstrated that upregulation of astrocytic
intermediate filaments is a crucial step and a hallmark of RG
[18]. RG is one of the pathophysiological features of retinal
damage. The vertebrate retina contains a specialized type of glia,
the Mu ¨ller glia. Like other glial cells of the CNS, Mu ¨ller cells
undergo RG following acute retinal injury or chronic neuronal
stress [19]. The overexpression of GFAP is the most sensitive non-
specific response to retinal disease and injury, and it may be
considered as the universal hallmark of retinal stress; such as
retinal injury and Mu ¨ller cell activation [20]. GFAP, which is
located primarily in Mu ¨ller cells, has specific immunoreactivities
that occur in all retinal eccentricities. Moreover, virtually every
pathologic alteration in the retina is accompanied by RG, that is,
by distinct changes of the Mu ¨ller cells properties [20]. Under these
pathological conditions, Mu ¨ller cells exhibit three crucial nonspe-
cific gliotic responses, which are considered as the ‘‘hallmarks of
glial cell activation’’, these are: [i] cell proliferation [21]; [ii]
changes in cell shape [hypertrophy] due to alterations in
intermediate filament [22]; and [iii] the upregulation of the
intermediate filament system composed of GFAP, vimentin, nestin
and synemin [23,24]. There are other gliotic characteristics such;
targeted cellular migration [25], changes in ion transport
properties [26], and secretion of signaling molecules such as
VEGF [27]. Successful inhibition of GFAP using antisense
oligonucleotides has also been reported by several groups
[28,29,30]. Ostensibly, gliosis is important for the protection and
repair of retinal neurons, yet some pathologies such as DR may be
exacerbated by RG properties [26,27].
YC-1; [3-[59-hydroxymethyl-29furyl]-1-benzyl indazole], is a
small molecule that inhibits cGMP breakdown. YC-1 is an agent
that has been considered as a novel type nitric oxide (NO)-
independent activators of soluble guanylate cyclase (sGC)
[31,32,33,34]. YC-1 is not an NO donor, however, it causes
activation of sGC especially in the presence of NO [35,36], while
binding to sGC at a different site from the heme [37]. We have
previously shown that YC-1 suppressed retinal new vessel growth
and formation in human retinal microvascular ECs, and retinal
explants [38]. Furthermore, we have demonstrated that YC-1
downregulates HIF-1a, HIF-2a, VEGF, EPO, ET-1, and MMP-9
protein expression in the human retinal microvascular ECs
[38,39,40]. The primary objectives of this investigation were to
determine; [i] whether ischemic exposure in the OIR mouse
model induces RG; [ii] whether YC-1 could target and hence
reverse RG, and [iii] whether YC-1’s effect is mediated through
the inhibition of the length and numbers of neovascular sprouts.
Materials and Methods
Ethics Statement
All experiments were conducted in compliance with the laws
and the regulations of the Kingdom of Saudi Arabia. In addition,
all animal protocols were approved by the Institutional Review
Board and conformed to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research statement of the
Association for Research in Vision and Ophthalmology.’’ This
research study was approved by the HEC/IRB Committee
(Human Ethics Committee/Institutional Review Board Commit-
tee) at the King Khaled Eye Specialist Hospital (KKESH). The
permit number/approval ID is ‘‘RP 0630-P’’.
Materials
YC-1 was purchased from A.G. Scientific [San Diego, CA] and
dissolved in sterile dimethyl sulfoxide [DMSO]. Fluorescein
isothiocyanate [FITC]-dextran 2,000,000 was purchased from
Sigma-Aldrich [St. Louis, MO]. Rabbit Anti-PDGF-B polyclonal
antibody was obtained from Abbiotec [San Diego, CA]. The
GFAP labeling was carried out by primary rabbit-anti rat GFAP
polyclonal antibody [Sigma, catalog number G9269] during
immunohistochemistry; or a monoclonal GFAP antibody pro-
duced in mouse [Sigma, catalog number G3893] for Western Blot
analysis. Polyclonal rabbit anti-b-actin antibody was purchased
from MBL Intl [Woburn, MA].
Tissue Culture
A transformed Mu ¨ller cell line [rMC-1] was kindly sent to us by
Dr. V.J. Sarthy. Mu ¨ller cell cultures were grown in DMEM
supplemented with 15% FBS, as well as with a fungicide mixture
and 0.5% gentamicin in a humidified atmosphere of 5% CO2/
95% air. Medium was changed every 2–3 days, and cells were
grown to confluence in a 150-mm dish. Cells were split into 60-
mm dishes and were used in the experiments when confluent.
R28 cells are immortalized rat retinal neurosensory/neuoroglial
progenitor cells, by transfection with Adenovirus 12S E1A into the
neonatal retinal tissue. The cells were a kind gift from Dr. Gail M.
Seigel [SUNY, Buffalo, NY]. R28 cells express genes characteristic
of neurons, as well as functional neuronal properties. R28 cells
were cultured in DMEM/F12 medium in a 1:1 mixture,
supplemented with 5% FBS, 1.5 mM L-glutamine, 7.5 mM
sodium pyruvate, 0.1 mM nonessential amino acids, 16 MEM,
0.37% sodium bicarbonate and 10 mg/ml gentamicin. Cells were
incubated at 37uC in the presence of 5% CO2.
Human retinal microvascular endothelial cells [hRMVEC]
were cultured in 150 ml of CS-C medium supplemented with 10%
FBS and in the presence of 1–100 mM YC-1 or DMSO [0.2%]
and incubated at 37uC.
In Vitro Hypoxia
Cells were placed in airtight chambers [BioSpherix, Redfield,
NY] and the O2 tension was maintained at 1.2% by using Pro-Ox
Targeting Reactive Gliosis by YC-1
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was purged with a gas mixture of 5.32% CO2, and 93.48% N2.
Cell Proliferation in a Co-culture System Model
To test the influence of Mu ¨ller cells [rMC-1] on the hRMVECs
proliferation, rMC-1 [2610
5 cells cm
22] were plated in a transwell
insert [Millipore, Billerica, MA] with 0.4 mm pores and allowed to
adhere overnight in 150 mL of CS-C complete medium [Cell Systems,
Kirkland, WA], supplemented with 10% FBS and incubated at 37uC
under normoxic [5% CO2/95% air]. The rMC-1 cells were then
incubated under normoxic [5% CO2/95% air], or hypoxic
conditions. To establish hypoxic conditions, cells were placed in
airtight chambers [BioSpherix, Redfield, NY] that were flushed with a
gas mixture of 5% CO2 and 95% N2. Oxygen concentrations within
these chambers were maintained at 1.2% using Pro-Ox Model 110
O2 regulators. After treating the r-MC-1 cells with YC-1 [100 mM]
for 24 hours, the insert was then placed into 24 well-plates, in which
hRMVECs were plated at 5610
3 cells cm
22 and allowed to adhere
overnight. hRMVECs proliferation was evaluated using 3, [4,4-
dimethylthiazol-2-yl]-2,5- diphenyl tetrazolium bromide [MTT]
colorimetric assay, at 24, 48, 72, and 96 hours after coculture. During
the last 4 hours of each day, 100 ml of 5 mg/ml MTT [Millipore,
Billerica, MA] was added in each well. Formed Formazan crystals
were dissolved in 600 ml DMSO and optical density was recorded at
492 nm. Experiments were performed on at least three independent
occasions. Data were presented as a percentage of negative control
proliferation with **P,0.01 being significant.
Cell Migration in a Co-culture System Model
Migration assay of hRMVECs was carried out using the transwell
insert with 8 mm pore size. The inserts were coated with Extracellular
matrix [ECM] [Millipore, Billerica, MA] and air-dry up. Chemotaxis
was induced by the control r-MC1cells or the r-MC1 cells that were
treated with YC-1 [100 mM], which were situated in the lower
compartment. hRMVECs suspension [final concentration, 5610
4
cells/well] was added to the upper compartment. After incubated for
24 hours, the filters were washed and then fixed and stained with
crystal violet [0.5% crystal violet and 20% methanol] for 30 min at
room temperature. The filters were washed with distilled water, and
the cells on the upper surface of the inserts were wiped with a cotton
swab. The number of cells per field that migrated to the lower surface
of the filters was determined microscopically. Five randomly chosen
fields were counted per filter. Data were presented as a number of
migrated cells [**P,0.01].
Quantitative RT-PCR by Molecular Beacon Assays
The message levels for PDGF-B and GFAP were quantified by
Real time RT-PCR. Gene-specific molecular beacons and primers
were designed to encompass the genes of interest, with beacon’s
annealing site to overlap with the exon-exon junctions for
additional specificity [Beacon Designer 6.0, Premier Biosoft
International, Palo Alto, CA, USA]. Threshold cycle [Ct] values
for the different samples were utilized for the calculation of gene
expression fold change using the formula 2 to the minus power of
delta delta ct. Fold changes in the PDGF-B and GFAP gene relative
to the b-actin endogenous control gene were determined by the
following equation: fold change=2
2D [DC
T
], where change in
threshold cycle [DCT]=CT [gene of interest]2CT [b-actin] and D
[DCT]=DCT [treated]2DCT [untreated].
Western Blot
Mu ¨ller cells [rMC-1] and R28 cells were seeded overnight in 6-
well plates [3610
5 cells/well]. Cells were treated with either YC-1
[25–100 mM] or DMSO [0.2% v/v] for 72 hours under normoxic
or hypoxic environments. Reactions were terminated by addition
of lysis buffer [Cell Signaling, Beverly, MA]. Protein content of the
cell lysates was determined according to the Bradford method
[Bio-Rad, Hercules, CA]. Aliquots [40 mg] of whole-cell lysates
were separated on 7.5% SDS-PAGE, and electro-transferred onto
polyvinylidene membranes [Amersham Pharmacia Biotech, Little
Chalfont]. After blocking with 5% nonfat dry milk in TBS-T, the
blots were incubated overnight with anti-[GFAP, PEDG-B, and b-
actin (internal control)] antibodies. Then blots were washed
3610 min washes in PBS/tween and subsequently incubated with
peroxidase-conjugated anti-mouse IgG secondary antibody at
1:3000. The signals were obtained by enhanced chemilumines-
cence [Amersham Biosciences], and visualized by exposure to X-
ray film. Upon completion of chemiluminescence, equal lane
loading was checked by Ponceau S Solution [Sigma, St. Louis,
MO]. X-ray films were scanned with a computer-assisted
densitometer [model G-710; Bio-Rad] to quantify band optical
density [Quantity One software; Bio-Rad].
GFAP Immunofluorescence
Mu ¨ller cells [rMC-1] and R28 cells [2610
4 cells per well] were
grown on 8-well chamber slides and cultured in 300 ml of their
growing media, which contained YC-1 [25–100 mM] or DMSO
[0.2% v/v] and incubated under normoxia or hypoxia for
48 hours at 37uC. YC-1 or DMSO was added 5 minutes prior
to the hypoxic incubation. Immunofluorescence of rMC-1 and
R28 cells was conducted by blocking slides in 0.1% blocking
solution (Invitrogen/Molecular Probes TSA Kit #2: T-20912)
followed by incubation for two hours with the primary rabbit-anti
rat GFAP polyclonal antibody [Sigma, catalog number G9269],
diluted in 0.1% blocking solution in a humid chamber for 2 hours
at 4uC. Negative controls included omission of the primary
antibody or its substitution with phosphate-buffered saline (PBS).
This was followed by incubating the slides with the horseradish
peroxidase (HRP)-labeled goat anti-rabbit IgG (H+L) secondary
antibody (#A-11008) in conjunction with a dye-labeled tyramide
[AlexaFluor 488] (Invitrogen/Molecular Probes Carlsbad, Cali-
fornia] [TSA Kit #2] for 1 hour in a dark humid chamber at
room temperature. These processes results in localized deposition
of the activated tyramide derivative (Stage 1). Hence, further dye
deposition, and therefore higher levels of signal amplification, can
be generated by detecting dye deposited in ‘‘Stage 1’’ with a
horseradish peroxidase (HRP)-labeled anti-dye antibody in
conjunction with a dye-labeled tyramide ‘‘Stage 2’’. Immunoflu-
orescence was visualized by using a Zeiss microscope [Zeiss LSM
510 META inverted confocal microscope equipped with argon
and helium/neon lasers using excitation wavelengths 488, on
Axiovert 200 M, Thornwood, NY]. Digitized images were
acquired utilizing excitation wave length 488 nm. Intensity values
of immunofluorescence staining of GFAP in rMC-1 and R28 cells
was analyzed and quantified using Metamorph
TM imaging
analysis software version 6.0 [Universal Imaging, Sunnyvale,
CA]. The staining intensity in our series ranged from a weak blush
to moderate or strong. The amount of cells staining with the
antibody was further categorized as focal [,10%], patchy [10%–
50%], and diffuse/multifocal [.50%]. For semiquantitative
analysis, focal and/or weak staining was considered equivocal
staining, and patchy or diffuse/multifocal staining was subcatego-
rized as either moderate or strong.
Animals and Experimental Design
C57BL/6J mice, from Jackson Laboratory [Bar harbor, ME]
were used in these experiments. All animal protocols were
Targeting Reactive Gliosis by YC-1
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ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research statement of the Association for Research in
Vision and Ophthalmology. Mice were divided into four separate
groups; [1] Non-treated mice grown under ambient conditions
[negative control]; [2] non-treated hyperoxia-exposed mice
[positive control]; [3] DMSO- treated hyperoxia-exposed mice
[sham-treated]; and [4] YC-1-treated hyperoxia-exposed mice
[drug-treated].
Mouse Model of Oxygen Induced Retinopathy
Retinal NV was induced in newborn mice as described
previously [41]. Briefly, P7 mice were exposed with their nursing
mother, for 5 days [between P7 and P12] to hyperoxic conditions,
by incubating them in an airtight chamber [PROOX 110
chamber O2 controller; Biospherix Ltd., Redfield, NY] ventilated
by a mixture of O2 and air to a final oxygen fraction of 7562%.
These incubation conditions induced vaso-obliteration and
subsequent cessation of vascular development in the capillary
beds of the central retina [41]. At P12, the mice were allowed to
recover in normal room air conditions and maintained for another
5 days [till P17], the day in which peak disease occurs. A condition
of relative hypoxia resulted between P12 and P17, and extensive
retinal NV developed in 100% of the mice. Age-matched animals
with the hyperoxia-exposed groups were maintained identically,
except they were exposed to room air [21% O2, 79% N2] for the
duration of the experiment. Animals were examined and sacrificed
on the same days.
Intravitreal Drug Injections
A group of hyperoxia-exposed animals [n=15] were injected
intravitreally [into both eyes] at P12 and P15 with 3 ml of YC-1
[100 mM] [drug-treated group]. Another group of hyperoxia-
exposed mice [n=15] were injected intravitreally [into both eyes]
at P12 and P15 with 3 ml of DMSO [0.2% (v/v)]. Non-treated
mice grown under ambient conditions, non-treated hyperoxia-
exposed mice, DMSO- treated hyperoxia-exposed mice and YC-
1-treated hyperoxia-exposed mice, were all examined at different
critical time points for qualitative assessment of the retinal
vasculature by fluorescein angiography.
Retinal Fluorescein Angiography and Visualization of
Retinal Vascularization
Deep anesthesia was induced by intraperitoneal injection of
ketamine [1%], xylazine [0.1%], and sodium chloride [0.9%] in a
concentration of 0.1 mL/10 g mouse body weight. Sternotomy
was performed, the mice were perfused through the left ventricle
with 600 mL of high-molecular-mass [2610
6 Da] FITC-dextran in
PBS [50 mg/ml], which was allowed to circulate for 2 minutes
before the animals were euthanatized and the eyes enucleated and
the flat mounts were prepared. Subsequent to retinal extraction,
all retinas were fixed in 4% paraformaldehyde for 24 hrs at 4uC. A
dissecting microscope was used to dissect the cornea with a
circumferential limbal incision, followed by removal of the lens
and vitreous. Microscissors were used to make four radial incisions
of the retinal eyecup in order to prepare retinal flat mounts on
glass slides. Flat mounts were immersed in Aquamount mounting
medium [Polysciences, Warrington, PA], coverslips were placed
over the retina, and the edges of the coverslips were sealed.
Immunohistochemistry
Mouse retinas were dissected and prepared for immunohisto-
chemical analysis, fixed in 4% paraformaldehyde in 0.1 M PBS for
15 min at room temperature and embedded in paraffin, sectioned
[5 mm]. Tissue sections were deparaffinized, hydrated, and later
exposed to heat-induced antigen retrieval using a microwave oven
[three 5-minute cycles in citrate buffer, pH 6.0], endogenous
peroxidase was abolished with methanol, and hydrogen peroxide
and nonspecific background staining was blocked by incubating
the tissue sections for 5 minutes in normal swine serum.
Subsequently, all slides were washed three times in PBS, and
incubated for 1 hour with primary anti–[PDGF-B, GFAP, and b-
actin] antibodies. The sections were washed with TBST and
incubated with EnVision Polymer HRP secondary antibody
[DAKO, Carpinteria, CA] for 30 minutes. All slides were stained
with DAB solution and counterstained with hematoxylin. Slides
were cover slipped [Permount; Fisher Scientific, Fairlawn, NJ] and
examined by light microscopy. Negative controls included
omission of the primary antibody or its substitution with
phosphate-buffered saline (PBS). Sections were photographed
under a microscope [Zeiss Axiovert 135, Thornwood, NY], and
images were acquired a digital camera [AxioCam, NY]. All retinas
were examined at 660 objective. The staining intensity in our
series ranged from a weak blush to moderate or strong. The
amount of cells staining with the antibody was further categorized
as focal [,10%], patchy [10%–50%], and diffuse/multifocal
[.50%]. For meaningful semiquantitative analysis, focal and/or
weak staining was considered equivocal staining, and patchy or
diffuse/multifocal staining was either subcategorized as either
moderate or strong staining. All Immunohistochemical analyses
were measured by Metamorph digital image software [Molecular
Devices, Sunnyvale, CA].
Quantitative Image Analysis of Immunohistochemical
Staining
GFAP and PDGF-B positive immunostaining in retinal tissue
sections (immunohistochemistry), as well as GFAP positive immuno-
labeling in rMC-1 and R28 cells (immunocytochemistry), were all
visualized and captured using AxioCam digital microscope camera.
The filter was set with excitation wavelengths 488. MetaMorph
image analysis software (version 7.1, Universal Imaging, Downing-
town, PA) was used for image processing and quantitative analysis of
GFAP and PDGF-B positive immunostaining. MetaMorph tools
were used to set the threshold and regions of interest (ROIs). All
images were captured at identical time and exposure settings, and
they were allprocessed to the same scale. Images werefirst segmented
on the basis of pixel intensity, which was done on a plane-by-plane
basis for an image stack. Briefly, each retinal section was scanned into
Metamorph, and five (5) fields/slide were chosen from each section
for analysis. One hundred and fifty (150) cells from each field were
selected. The saved file was used to calibrate each image for specific
pixel size. With the help of a free drawing tool, GFAP and PDGF-B-
stained areas were chosen and measured in total-pixels area. A
threshold encompassing an intensity range of 100–250 gray-scale
values was applied to the ROIs in the least brightly stained condition
first. The data were also read and investigated by Matlab v6.5 script
file software, which counted the total number of pixels that were
above threshold value. This number was divided by the total number
of pixels in each image to yield percent fluorescent pixels. To correct
for background fluorescence, the threshold was adjusted for each
experimental series, with concomitantly processed negative controls
used as the guide for setting background fluorescence. The
background fluorescence intensities per pixel were subtracted from
the experimental data by using a one-step erosion procedure, and
then all remaining objects were counted. The same threshold was
subsequently applied to all images. GFAP and PDGF-B was
considered to be positive only when it exceeded the established
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the total area selected was then calculated. The total GFAP and
PDGF-B fluorescence intensity per cell was calculated, and the
average fluorescence intensity per pixel was determined by dividing
the total intensity by the area of the cell measured in pixels. This was
followed by measuring the average fluorescence intensity in each
field. Data from multiple fields as indicated over several experiments
were used to obtain the final results. The number of immunopositive-
stained cells per image was then expressed per um
2,a n dt h ea v e r a g e
number per section was determined among five separate fields.
Statistical Analysis
Analysis was performed utilizing ANOVA for multiple variables
and with t–Tests for comparison of 2 groups with normal
distribution. For the analysis of Real Time RT-PCR data;
immunohistochemistry data; Western Blot data, analysis was
performed with ANOVA for multiple variables and with t–Tests.
Data are expressed as mean 6 SEM from at least 3 independent
experiments. Significance was defined as *P,0.05; **P,0.01;
***P,0.001.
Results
Analyses of the Retinal Vasculature and the Progression
of Retinal NV
At P2 only budding superficial vessels were observed occupying
a single plane around the optic disc [Fig. 1; P2]. In P4 wild type
mice, the retinal vasculature was organized uniformly and was
evenly spaced over the superficial retina and vessels grew into the
deeper layers of the retina [Fig. 1; P4]. The vascular density and
the number of branch-surrounded spaces increased at P4. In
addition, the margin of the developing BVs on the surface of the
retina is located halfway between the optic nerve and the
peripheral edge of the retina. This is followed by development of
a capillary network at P7. During P7, superficial vessels cover
about 80% of the retina [Fig. 1; P7]. At this stage sprouts from
superficial vessels begin to grow into the retina to form the
intermediate and deep capillary beds. In addition, the hyaloidal
vessels start to regress. Over the course of the next week, the
primary superficial network extended toward the periphery,
reaching the far periphery at P12. Angiogram of P12 FITC-
dextran-perfused retinal flat mounts of the OIR model prepara-
tions displays the effects of 5 days of hyperoxic-exposure [Fig. 1;
P12]. On return to normoxia at P12, a relative state of ischemia in
the poorly vascularized retina is associated with the excessive re-
growth of superficial vessels, leading to abnormal sprouting at the
interface between retina and vitreous. Retinas at P12 exhibit
typical signs of central non-perfusion of the retina and a drastic
regression in the vascular network, leaving only the major vessels
and practically no capillary network. The peripheral retina still
showed evidence of a vascular network, but, in general, the deep
vascular plexuses had completely failed to form. By P15 the retinal
ischemia initiates an aggressive neovascular response at the
interface of the perfused retinal periphery and the ischemic
central capillary beds [Fig. 1; P15]. On P17, the vascular network
of the O2-injured retinas was significantly altered as demonstrated
by an increase in retinal NV. These retinas displayed the features
indicative for a strong ongoing vasoproliferative response: central
capillary-free regions, vessel tortuosity and BV tufts [Fig. 1; P17].
YC-1 Attenuates Neovascular Sprouting in the OIR Mouse
Model
Data from [Figs. 2A–F] demonstrated that retinal NV in the
O2-injured and the DMSO-treated retinas was associated with the
presence of neovascular sprouts and the formation of cordlike or
tube-like structures. However, YC-1 treatment has disturbed and
suppressed the development and elongation of neovascular sprouts
[Figs. 2C–F]. YC-1 significantly and dose-dependently reduced
the total length [Fig. 3A] and the number [Fig. 3B] of neovascular
sprouts, as compared to DMSO-treated retinas.
YC-1 Reverses Retinal Reactive Gliosis and Retinal
Neovascularization, in vivo and in vitro
In order to investigate the mechanisms via which YC-1 reverses
retinal RG and NV in the OIR mouse model, we measured the
transcription of key genes that are associated with both; RG and
NV, as markers of a putative recovery. By using the primers,
which were summarized in [Fig. 3C]; Real Time RT-PCR data
have indicated that there was a significant enhancement of GFAP
gene expression levels in the non-treated ischemic retinas as
compared with the retinas from animals that were placed under
ambient conditions. The effects of DMSO-treatment on the gene
expression profiles paralleled those seen in the non-treated
ischemic retinas. YC-1 treatment significantly attenuated
[**P,0.01] the message levels of GFAP expression [Fig. 3D].
YC-1 treatment [100 mM] reduced ischemia-induced overexpres-
sion of GFAP at the message [by 64.1460.5%], as compared to
DMSO-treated controls. Furthermore, there was a significant
alteration in the mRNA levels of PDGF-B, between YC-1-treated
groups and non-treated and DMSO-treated controls. There was a
significant upregulation in the mRNA levels of PDGF-B in the
ischemic retina as compared to normoxic retinas [Fig. 3E].
Treatment of the animals with YC-1 [100 mM] significantly
[**P,0.01] attenuated the ischemia-induced overexpression of
PDGF-B at the message level of [by 70.2760.04%], as compared
to DMSO-treated retinas.
Our in vitro studies have revealed that post hypoxic exposure, the
level of GFAP mRNA expression was significantly increased over
the normoxic control, which displayed a basal expression levels
[Fig. 3F]. The effects of DMSO-treatment on the gene expression
patterns in both cell types paralleled those seen in the non-treated
ischemic retinas. Treatment of r-MC1 and R28 cells with 25–
100 mM YC-1 resulted in significant dose-dependent attenuations
in the message levels of GFAP expression, when compared with
DMSO-treated hypoxic cells. At 100 mM, YC-1 treatment
downregulated the hypoxia-induced overexpression of GFAP at
the message level in rMC-1 cells [by 71.4260.02%], and R28 cells
[by 58.6260.02%], respectively. Data were normalized to b-actin
mRNA levels. In addition, Real Time RT-PCR data have
demonstrated that after 48 hours of hypoxic exposure, the levels
of PDGF-B mRNA expression were significantly increased over the
normoxic control, which displayed low gene expression levels
[Fig. 3F]. Treatment of both cell lines YC-1 [25–100 mM] resulted
in significant dose-dependent attenuations in the message levels of
PDGF-B expressions, when compared with DMSO-treated
hypoxic cells. Treatment of r-MC1 and R28 cells with YC-1 at
100 mM downregulated the hypoxia-induced overexpression of
PDGF-B at the message level in rMC-1 cells [by 7560.03%], and
R28 cells [by 50.0060.02%], respectively.
Immunohistochemical Expression and Localization of
PDGF-B, and GFAP, in vivo
In the Non-Treated Normoxic Retinas [Fig. 4], PDGF-B expression
was focal and sparse, and it was predominantly localized in the
ILM, NFL, GCL, and INL. Furthermore, the Non-Treated Ischemic
Retinas exhibited a pattern of PDGF-B overexpression and
immunohistolocalization, which was particularly prominent in
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22244Figure 1. Analyses of Retinal Vascular Development in the Normal Retinal Vasculature and the Neovascular Retina. Mice were
perfused with fluorescein-labeled dextran. Normal mice were analyzed P2 [A], P4 [B], and P7 [C]. Exposure of mice to 75% O2 between P7–P12 led to
rapidly progressive vaso-obliteration of the retinal vasculature over. Retinal NV was analyzed in the OIR mice on P12 [D], P15 (OIR) [E], and P17 (OIR)
[F]. [n=15 per group]. bar: 300 mm.
doi:10.1371/journal.pone.0022244.g001
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22244Figure 2. The Influence of YC-1 on Neovascular Sprouts Number and Length. Images exhibit a higher magnification of growing tips of BVs that
reveal multiple neovascular sprouts growing at multiple angles including both along and above the plane of the section. Image along the leading edge of
vascularization from; [A] Non-treated ischemic retinas; [B] DMSO-treated retinas; [C, D, E, and F] represent retinas from animals that were injectedw i t hY C - 1
[25–100 ml]. neovascular sprouts lengths and numbers were not influenced by DMSO treatment. Whereas treatment with YC-1 significantly and dose-
dependently inhibited the number and the length of neovascular sprouts. [n=5 per group].
doi:10.1371/journal.pone.0022244.g002
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22244the ganglion cells [GCL], as well as a significant upregulation in
the positive immunoreactivities of PDGF-B, which was present in
the ILM, and within the NFL, and the inner segments of the
photoreceptor cells [INL]. The immunoreactivity was diffuse with
strong PDGF-B overexpression that was primarily augmented in
the NFL, GCL, and INL, as compared to Nontreated Normoxic
Retinas and the YC-1-Treated Retinas. In the DMSO-Treated Retinas,
the immunohistolocalization pattern of PDGF-B was identical to
the pattern that was shown in the ischemic controls. In the YC-1-
treated retinas; PDGF-B immunoreactivity was significantly
inhibited [by 57.5960.01%], as compared with DMSO-treated
retinas, and the immunostaining was primarily focally localized in
the ILM, GCL, and INL [Fig. 4].
Our immunohistochemistry data have demonstrated that the
Nontreated Normoxic Retinas exhibited staining signals for GFAP
immunoreactivity, which tended to be sparse and focal and
primarily localized in the ILM and GCL [Fig. 5]. However, the
Nontreated O2-Injured and the DMSO-Treated O2-Injured Retinas
exhibited strong staining of GFAP expression, primarily in the
ILM, nerve fiber layer [NFL], GCL, and inner nuclear layer
[INL] of the ischemic retinas. In addition, there was a strong
staining for GFAP immunoreacreactivity in Mu ¨ller cell processes
throughout the retina. In contrast, YC-1-Treated retinas displayed a
significant downregulation in GFAP immunoexpression as com-
pared to DMSO-Treated Retinas [Fig. 5]. in addition, GFAP
expression was weak ‘‘focal’’, sparse, sporadic and primarily
localized in the ILM, NFL, and the GCL regions of these retinas.
Our data has indicated that YC-1 treatment [100 mM] has
reduced ischemia-induced overexpression of GFAP protein levels
[by 65.5260.02%], as compared to DMSO-Treated Controls [Fig. 5].
Our data analysis of PDGF-B and GFAP expression in the
retinal tissues indicated that YC-1 significantly reduced the
number of PDGF-B (+) cells and GFAP (+) cells as compared to
DMSO-treated retinas [Fig. 6A], which indicated that YC-1
exhibited anti-reactive gliosis and anti-angiogenic properties, in
vivo.
Inhibition of ECs Proliferation and Migration in the
Coculture System via the Anti-angiogenic Effects of YC-1
on Mu ¨ller Cells
Our proliferation assay in a coculture system model has
demonstrated that rMC-1cells-hRMVECs coculture significantly
increased hRMVECs proliferation compared to solo hRMVECs
culture [Fig. 6B and 6C] under normoxia and hypoxia. Data have
indicated that coculture under hypoxic conditions had a
synergistic effect. Although there was insignificant difference in
the hRMVECs proliferation while being cocultured with non-
treated rMC-1 cells under normoxic or hypoxic conditions; the
proliferation of hRMVECs was significantly suppressed when
rMC-1 cells were treated with YC-1, under normoxic and hypoxic
conditions. Furthermore, our migration assay in a coculture
system model has shown that hRMVECs were found to extend
through 8.0 mm Transwell pores in a transmigration assay with
Mu ¨ller cells grown in the well [Fig. 6C and 6D]. Coculture of
hRMVECs with Mu ¨ller cells under hypoxia resulted in a
significant increase in hRMVECs migratory activity over the
levels of [rMC-1 cells/normoxia group]. Whereas the rMC-1 cells-
induced hRMVECs migration was significantly attenuated by YC-
1 treatment under normoxic [rMC-1 cells/hRMVECs (normoxia
group)] and hypoxic conditions [rMC-1 cells/hRMVECs (hypoxia
group)] [Fig. 6C and 6D].
YC-1 Restrains Hypoxia-Induced Upregulation of GFAP
and PDGF-B Protein Levels, in Glial Cells
In order to investigate the mechanisms via which YC-1 reverses
retinal RG and NV in our cell culture models, we quantified the
expression of GFAP and PDGF-B, respectively, as key protein
molecules that are associated with RG and NV. Our Western
immunoblot data have indicated that rMC-1 and R28 cells
cultured under normoxia exhibited suppressed protein levels of
GFAP protein, whereas GFAP was overexpressed 72 hours post-
hypoxic exposure [Fig. 7A]. In the DMSO-treated hypoxic cells,
GFAP protein expression remained relatively stable, when
compared with non-treated hypoxic cells. This increase in GFAP
expression was measured by densitometry [Fig. 7B]. In both cell
types and under hypoxic conditions; YC-1 treatment dose-
dependently inhibited the hypoxia-induced GFAP protein levels
in by [78.5760.02%] in rMC-1cells, and by [81.4460.02%] in
R28 cells, respectively. Furthermore, Western immunoblot
analysis have indicated that rMC-1 and R28 cells cultured under
normoxia exhibited low immunoreactivity signals of PDGF-B
protein expression, while this signal was overexpressed after
72 hours of hypoxic exposure [Fig. 7A]. There was a significant
increase in PDGF-B protein expression, as measured by
densitometry [Fig. 7B], compared to normoxia. In both cell types
and under hypoxia, YC-1 inhibited the hypoxia-induced upregu-
lation of PDGF-B protein levels in a dose-dependent manner,
compared with DMSO-treated hypoxic cells. At 100 mM, YC-1
treatment inhibited the hypoxia-induced protein overexpression of
PDGF-B [by 77.5560.01%] in rMC-1cells, and [by
79.1660.01%] in R28 cells, respectively.
Our immunofluorescence staining of GFAP demonstrated that
non-treated rMC-1 and R28 cells cultured under hypoxia
displayed enriched GFAP protein fluorescence immunoreactivity,
with strong cytoplasmic staining of both cell types [Fig. 8; positive
control]. Hypoxic cells exhibited significant (**P,0.01) increase in
Figure 3. YC-1 Reverses Retinal Reactive Gliosis and Retinal Neovascularization, in vivo and in vitro. Neovascular sprouts from DMSO-
treated retinas had approximately similar lengths as the non-treated ischemic retinas [A]. YC-1 treated animals exhibited a significant and a dose-
dependent decrease in neovascular sprouts lengths as compared to DMSO-treated retinas. [ANOVA, ***P,0.001; **P,0.01 between YC-1 and DMSO]
[A]. DMSO has no influence on the number of neovascular sprouts [B]. Whereas YC-1 exhibited a significant and a dose-dependent decrease in
neovascular sprouts number [B]. [ANOVA, ***P,0.001; **P,0.01 between YC-1 and DMSO]. There were 24 neovascular sprouts/retina that were
averaged. [n=5 per group]. By using primer sets [C]; Real Time RT-PCR analyses, in vivo [D and E] indicate that the levels of GFAP and PDGF-B mRNA
were increased in the non-treated ischemic retinas, while non-treated normoxic retinas exhibited extremely low levels. Treatment of ischemic retinas
with dual injections of YC-1 resulted in a significant knockdown of PDGF-B [**P,0.01] and GFAP [**P,0.01] gene expression when compared with
DMSO-treated controls. ANOVA; Mean 6 SEM of mRNA level normalized to b-actin were calculated, [***P,0.001 and **P,0.01, as compared to
DMSO-treated retinas]. Data are representative of 3 independent experiments. Real Time RT-PCR analysis, in vitro [F] indicate that post-culturing R28
and rMC-1 cells under normoxic and hypoxic conditions; the mRNA levels of GFAP and PDGF-B were upregulated in all non-treated hypoxic cells,
while normoxic cells exhibited remarkable low mRNA levels. Treatment of hypoxic R28 and rMC-1 cells with various concentrations of YC-1 resulted in
a significant inhibition of GFAP and PDGF-B, mRNA expression as compared to DMSO-treated controls. ANOVA was used for statistical analyses. Mean
6 SEM of mRNA level normalized to b-actin were calculated, [***P,0.001 and **P,0.01 as compared to DMSO-treated hypoxic control. Data are
representative of 3 independent experiments].
doi:10.1371/journal.pone.0022244.g003
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22244Figure 4. Immunohistochemical Analysis of PDGF-B, in vivo. Photomicrographs of retinas from various OIR groups that were immunostained
for PDGF-B. The expression of PDGF-B was upregulated in the non-treated ischemic and DMSO-treated groups, compared with non-treated normoxic
group. While all protein immunoreactivities were downregulated in the YC-1-treated group, compared with DMSO-treated groups. Data are
representative of 3 independent experiments. Scale bar: 140 mm.
doi:10.1371/journal.pone.0022244.g004
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e22244Figure 5. Immunohistochemical Analysis of GFAP, in vivo. Photomicrographs of retinas from OIR groups that were immunostained for GFAP.
GFAP was overexpressed in the non-treated ischemic and DMSO-treated groups, compared with non-treated normoxic group. Whereas all GFAP
immunoreactivities were downregulated in the YC-1-treated group, compared with DMSO-treated groups. Data are representative of 3 independent
experiments. Scale bar: 140 mm.
doi:10.1371/journal.pone.0022244.g005
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PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e22244Figure 6. YC-1 Exhibits Anti-Reactive Gliosis and Anti-Angiogenic Properties, in vivo and in vitro. Assessments of retinal
immunohistochemical analysis exhibit the values that were obtained from at least 5 retinal fields were used to calculate the average pixel
intensity value/retina [A]. Bar graphs exhibit the area of staining of GFAP and PDGF-B in all four groups. Values [mean 6 SEM], from 3 separate
experiments from at least 10 images from 4 different eyes/group. [***P,0.001 and **P,0.01 as compared to DMSO-treated retinas]. [B] Coculture
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exhibited limited areas of very weak ‘‘blush’’ GFAP staining [Fig. 8;
negative control]. Furthermore, there was a strong positive GFAP
staining signal deposited over the cytoplasms of the DMSO-
treated cells cultured for 48 hours under hypoxia [Fig. 8; DMSO].
This intense positive staining was diminished with YC-1
treatment. No GFAP staining was observed in experiments in
which the primary antibody was omitted and/or substituted with
PBS (data not shown). rMC-1 cells treated with 25 mM YC-1
displayed the presence of cytoplasmic localization but then with
weaker equivocal ‘‘weak’’ staining intensity. Whereas, a stronger
diffuse cytoplasmic GFAP staining was observed in R28 cells.
Treatment of rMC-1 and R28 cells with 25 mM YC-1 under
hypoxia for 48 hours displayed a significant inhibitory effects
(42.10% and 48.78% inhibition, respectively), compared to
DMSO-treated hypoxic controls. At 50 mM YC-1, GFAP
cytoplasmic staining levels was drastically reduced in both cell
types, as compared with non-treated controls cultured under
hypoxia. At [50 and 75 mM], YC-1 had significant inhibitory
effects on GFAP protein expression in both cell types, as compared
to hypoxic controls. There was a strong reduction of GFAP
cytoplasmic staining levels in both cell types, as compared with
non-treated controls cultured under hypoxia. Treatment of rMC-1
and R28 cell lines with 50 mM YC-1 for 48 hours under hypoxia,
caused a significant inhibition of 44.73% (**P,0.01) and 50%
(*P,0.05) respectively, as compared with non-treated hypoxic
controls. Whereas treatment of cells with 75 mM YC-1 for
48 hours under hypoxic conditions had significant (**P,0.01)
down-regulatory effects on GFAP protein expression in both cell
types, whereas GFAP inhibition in rMC-1 and R28 cells were
52.63% and 56.09%, respectively, as compared with non-treated
hypoxic controls. At 100 mM YC-1, there were few stained regions
that were still detected in the cytoplasm of YC-1-treated cells. At
100 mM, YC-1 displayed significant (**P,0.01) 78.94% and
70.73% folds of inhibition in rMC-1 and R28 cells, respectively, as
compared with non-treated hypoxic controls. Our data indicated
that YC-1 significantly reduced GFAP protein levels in R28 and
rMC-1 cells under hypoxia and in a dose-dependent fashion
[**P,0.01] [Fig. 8 and bottom graphs in Fig. 8].
Discussion
Reactive gliosis [RG] is one of the pathophysiological features of
retinal damage. RG includes morphological, biochemical, and
physiological changes of Mu ¨ller cells; these alterations vary with
type and severity of damage. The molecular mechanism(s) leading
to RG is not fully elucidated. In this study we have investigated the
effects of YC-1, a small molecule inhibitor of hypoxia induced
factor -1 (HIF-1), on experimentally induced retinopathy using the
OIR mouse model. YC-1 is a novel type nitric oxide (NO)-
independent activators of soluble guanylate cyclase (sGC)
[31,32,33,34]. YC-1 is not an NO donor, however, it causes
activation of sGC especially in the presence of NO [35,36], while
binding to sGC at a different site from the heme [37]. Data has
previously demonstrated that sustained hyperoxia effectively
preserved astrocytes in the central retina in spite of extensive
damage to the capillary networks and prevented the reactive
expression of GFAP in the Mu ¨ller glia [42]. In addition, the OIR
mouse model has been extensively used because it constitutes
several clinical manifestations that are analogous to the retinop-
athy of maturity [ROP], and mimics the important aspects of
PDR; the most common ischemic retinopathy in patients [43].
Since (i) YC-1 induces physiological RV in the OIR model [39];
(ii) a significant segment of this process seems to occur in the INL,
OPL, ONL, and OLM retinal cell layers; and (iii) the fact that
Mu ¨ller cells processes span the entire retina and extend from the
INL to the OLM, the possibility existed that YC-1 maybe acting
directly on retinal glial cells. We found that GFAP [the hallmark of
RG] was expressed at low levels under normoxic conditions, in vitro
and in vivo, which is in concordance with what’s been previously
reported [44]. However, upon exposure to hypoxic/ischemic
conditions, GFAP levels were increased both at the message and
the protein levels. These results are in agreement to what has been
previously reported by other studies, which indicated that hypoxic
subculture of Mu ¨ller cells causes a dramatic upregulation of GFAP
in vitro [45]. Retinal ischemia/hypoxia have been shown to cause
an increase in gene and protein expression of GFAP in Mu ¨ller cells
within 1–3 h and that expression extended the inner processes of
Mu ¨ller cells [up to the INL] [46,48]. It has been noted that
astrocytes are the only cells in the retina that express GFAP, but
after various insults such as retinal detachment, ischemia, light
damage, or genetic photoreceptor degeneration, Mu ¨ller glia
become GFAP-positive [49,50], whereas Normoxic Retinas expressed
low levels of GFAP expression that was confined to the ILM and
GCL regions of the retina, with no Mu ¨ller cell processes staining.
In the Nontreated Ischemic Retinas and DMSO-Treated Ischemic Retinas;
GFAP was significantly upregulated in the ILM, GCL, IPL, and
INL with clear staining at Mu ¨ller cell processes, and was overly
expressed due to the damage to the retina by ischemia after
vascular pruning, which indicates glial reactivity.
YC-1 displays antiangiogenic activities in vitro and in vivo
[38,39,40]. YC-1 possesses novel pleiotropic effects pertaining
the making, toning, maintaining the structural and functional
integrities of BVs. Our results show that YC-1 repressed GFAP
expression at the message and the protein levels, in the ischemic
retinas and in glial cells, suggesting a reversal of RG. To our
knowledge no other report to date has demonstrated the ability of
small anti-angiogenic molecules to target and reverse RG.
Previous studies have demonstrated that levels of PDGF-B were
increased after ischemic injury [51]. Since YC-1 inhibits platelet
aggregation, it is plausible that some of its anti-angiogenic effects in
retinal vasculopathies are mediated through PDGF-B. Our data
demonstrate that under hypoxic conditions PDGF-B is expressed at
significantly higher levels compared to normoxic retinas. YC-1-
treated retinas exhibited a significant inhibition of PDGF-B mRNA
and protein levels as compared to DMSO-treated retinas. It is
noteworthy that other groups have attributed the retinal production
of PDGF-B to the ganglion cells [52]. Our data indicated Nontreated
Ischemic Retinas and DMSO-Treated Ischemic Retinas have both
exhibited an overexpression of PDGF-B, which was predominantly
localized within the cell bodies of the retinal neurons; and it was
mostly localized to the Mu ¨ller cell end-feet at the ILM with diffuse/
multifocal overexpression at the NFL, GCL, and INL. Our data
models. [i] Cell proliferation assay model. [ii] Cell migration assay model; were both utilized to investigate the effects of YC-1 on the proliferation [C]
and migration [D] of ECs in a coculture system. hRMVECs growth curves from four groups were depicted. Coculture group had a higher proliferation
and migration rate of hRMVECs cells than that of hRMVECs solo [**P,0.01]. Hypoxia significantly increased hRMVECs proliferation and migration rate
in the coculture system [**P,0.01, rMC-1/hypoxia vs. rMC-1/normoxia]. After rMC-1 cells were treated with YC-1 [100 mM], the proliferation and the
migration rate of hRMVECs were significantly inhibited compared with the rMC-1/hypoxia group. [**P,0.01, YC-1-treated rMC-1/hypoxia vs.
nontreated rMC-1/hypoxia]. Data are representative of 3 independent experiments.
doi:10.1371/journal.pone.0022244.g006
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PLoS ONE | www.plosone.org 13 July 2011 | Volume 6 | Issue 7 | e22244Figure 7. YC-1 Restrains Hypoxia-Induced Upregulation of GFAP and PDGF-B Protein Levels, in Glial Cells. Western Blot analysis
indicated that protein expression levels were elevated markedly in the non-treated hypoxic cells [A]. In YC-1-treated hypoxic cells, GFAP and PDGF-B
protein expression were significantly decreased in a dose-dependent fashion, compared with DMSO-treated hypoxic cells. Statistical significancew a s
determined byANOVA[**P,0.01]. Dataarerepresentativeof 3 independent experiments.ThedensitometricanalysisofWestern Blotdata [B]represents
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PLoS ONE | www.plosone.org 14 July 2011 | Volume 6 | Issue 7 | e22244the intensities of GFAP and PDGF-B protein expressions in rMC-1 and R28 cells relative to those of b-actin expression, whereas the relative ratio of
hypoxia control was defined as 100. Values, shown as the mean 6 SEM, from 3 separate experiments with a total sample size of 6. [**P,0.01 as
compared to DMSO-treated hypoxic control].
doi:10.1371/journal.pone.0022244.g007
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immunoreactivity was observed in Mu ¨ller cell end-feet of the neural
retina. The source of this PDGF-B was next investigated in a series
of in vitro experiments in which glial cells were subjected to hypoxic
conditions for 72 hours. Such treatment caused a profound increase
in PDGF-B at the message and the protein levels. Taken together,
these findings suggest the contribution of Mu ¨ller cells to retinal
PDGF-B and implicate an autocrine mechanism of PDGF-B on
Mu ¨ller cells. It is noteworthy that our results are in concordance
with previous studies [8], which demonstrated that glial cells may
utilize the elevated levels of PDGF-B to proliferate, and conse-
quently causing RG. In this manuscript, we demonstrate that
hypoxia has triggered RG within 72 hours of exposure in vitro
[rMC-1 and R28 cells], whereas the ischemic retina has fully
developedRGatP17 invivo[OIR mousemodel].Thesefindings are
in concordance with previous studies [20].
Hypoxia inducible factor-1 [HIF-1] is a master regulator that
controls the transcriptional activation of VEGF signaling and other
hypoxia-inducible genes [53]. Like VEGF; PDGF-B is a hypoxia-
regulated gene [54]. Our previous studies have revealed that YC-1
inhibits HIF-1and other proangiogenic factors in the ischemic retinas
of the OIR mouse model [38,39,40]. It is therefore possible that YC-
1’s effect on RG may be mediated through the inhibition of HIF-1-
signaling, since PDGF-B protein molecule is downstream of HIF-1.
Throughout our current and previous investigations, we have
demonstrated that targeting hypoxia and HIF-1 signaling maybe
considered as a therapeutic modality to target several downstream
angiogenic molecules, such as PDGF-B, which play crucial roles in
ischemic retinopathies. Moreover, sprouting angiogenesis involves
collectivemigrationprocesses[55].Tipcellsaredistinguishedbytheir
strong expression of PDGF-B mRNA and VEGFR2 mRNA and
protein, implying that tip cells may have a distinct gene expression
profile [56] and regulate the coordinated processes of neovascular
sprouting. These findings would be consistent with our current data,
which revealed that the decrease in the length and number of
neovascular sprouts in YC-1-treated retinas, were both highly
associated with the downregulatory effects of YC-1 on PDGF-B
expression. Taken together, this study has demonstrated that YC-1
could be exploited as valuable therapeutic modality in the treatment
of RG in the ischemic retina. Antagonists of PDGFs may help to
reduce scarring, but may also synergize with VEGF antagonists to
reduce NV possibly through pericytes, which provide survival signals
for ECs of new vessels [57]. Kinase inhibitors that block both VEGF
and PDGF receptors are some of the most efficacious drugs for the
treatment of ocular NV in animal models [58,59]. Our current study
has revealed that YC-1 inhibited GFAP and PDGF-B, while our
previous studies have indicated that YC-1 inhibited VEGF
[38,39,40]; such data corroborate other studies, which demonstrated
that combining antagonism of PDGFs with blockade of VEGFs may
be a useful strategy for treatment of ocular NV [59]. Successful
inhibition of GFAP using antisense oligonucleotides has also been
reported by other investigators [28,30].
Our previous investigations have demonstrated the presence of
spatial overexpression of VEGF, ET-1, iNOS, and MMP-9 in the
neovascular retina of the OIR mouse model [39]. Whereas in our
current study, we demonstrate a concomitant expression of GFAP
and PDGF-B, which occur during ischemic retinal NV. It was
reported that neoangiogenesis was associated with reactive
astrogliosis and was correlated to increased reactive astrocytosis
and associated VEGF expression [60]. In addition, multiple lines
of evidence have demonstrated a pivotal role of the endothelin
system in stimulating RG. The production of ET-1 is stimulated at
injured brain sites [61], and cerebral ischemia specifically triggers
astrocytes to release it [62]. Additionally, ET-1 is highly expressed
in reactive astrocytes from patients who have suffered from various
neurological disorders, including cerebral infarcts, and Alzhei-
mer’s disease [63]. Moreover, it was suggested that ET-R-
associated pathways might represent important targets to control
RG [64]. In injured nerve tissues, astrocytes become the reactive
phenotype, which causes the overexpression of MMP-9 [65]. In
addition, the same study has suggested that ETs are one of factors,
which stimulate astrocytic MMP-9 productions. Moreover,
previous studies have suggested that iNOS expression may serve
as an index of RG [66,3]. Taken together, our findings and those
of others suggest a crosstalk between RG and NV. Our study
demonstrates that the neuroprotective mode of YC-1’s action,
which blunts the ischemic insult to the retina may have similar role
in protecting ischemia-induced neural damage.
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